Field of Healthcare (Heilmittelwerbegesetz – HWG), last amended on 20 System and their Employees were published in December reading of the proposal in November In the second part of .. Germany, the Remedies Advertising Act (Heilmittelwerbegesetz – HWG) were in line with the. Health on the Net Foundation. (accessed 9 June ). I S. ) vom 26 April Heilmittelwerbegesetz.  ICMJE.
|Country:||Trinidad & Tobago|
|Published (Last):||8 February 2016|
|PDF File Size:||17.20 Mb|
|ePub File Size:||3.23 Mb|
|Price:||Free* [*Free Regsitration Required]|
According to a judgment of the Higher Regional Court of Cologne, the promotion of drugs using rebates is only permissible if the rebates are product-related and not granted on products other than the promoted ones Higher Regional Court of Cologne, judgment of 23 Februaryhrilmittelwerbegesetz.
Such items include inexpensive software-applications in particular smart phone apps which support diagnostic analysis and therapy of patients, as long as they are related to products and indications of the member heilmitetlwerbegesetz.
Healthcare professionals may be involved in heilmittelqerbegesetz research exercises relating to such marketing materials if it is ensured that the involvement cannot be deemed to circumvent prohibition against promoting unauthorised medicinal products or indications. Home Practice area Pharmaceutical Advertising Germany. The medicinal product is imported solely on the basis of a physician’s prescription.
With regard to rebates granted by mail order pharmacies established in other Member States and which are in contradiction with the German pricing rules set out in the AMPreisV, a political discussion is ongoing on how to implement the ECJ ruling described above see question 4. PMS-Studies may only be conducted if the pharmaceutical company has a legitimate and objective interest in obtaining the data and a written agreement has been concluded with the physician.
What regulatory authority is responsible for supervising marketing activities regarding professionals?
Pharmaceutical Advertising 2018 | Germany
The HWG foresees a limited number of exceptional rules, e. A marketing authorisation obtained in Germany gives the market authorisation holder the right to sell the hei,mittelwerbegesetz medicinal product in Germany. For example, may information on such medicines be discussed, or made available, at scientific meetings? Therefore, the restrictions contained in the HWG shall not be interpreted as being more restrictive than the restrictions in the EC-Directive.
The recent launch of iHCE, a full-spectrum healthcare ‘super agency’, illustrates the need for a cost-effective and actionable multi-disciplinary approach to reach and motivate target audiences with greater speed and relevance.
Country report: The healthcare market in Germany – PMLiVE
The information may also be heilmittelwerbegeserz on a pan-European website of affiliated companies if the information relating to the member company of the FSA can be accessed there separately. Based on the wording of the amended ordinance, however, it is not clear whether the amount of EUR has to be interpreted as a maximum amount for reasonable hospitality costs, thus an amount of EUR being unreasonable, or whether the wording can be understood as setting forth the generally reasonable amount and exceptions thereto may be justified depending on the individual circumstances of each case.
For example, apps to help patients adhere to treatment and doctors monitor the heilmittelwerbegeeetz can have significant impact.
A list of legal examples is set out in the UWG, heilmittelwerbegeseyz applies to company-related advertising statements sections 4 and 5, UWG. Consequently, the risk of infringement of the HWG is higher the more such scientific information relates to a specific product or product trademark, or is used in relation to the advertising activities for an unauthorised product.
Although in this case the value thresholds do not apply, it has to be noted that the items value has to be of subordinate importance compared to the medicinal product to which it is supposed to be an accessory.
In a study, Klaus Weber and colleagues claim that the anti-biotech social movement, led by the Green party, altered the public perception of biotechnology, by concentrating on the potential dangers of using genetically-engineered techniques to manufacture drugs. Early studies showed manufacturers dropped prices to the level of the reference price and it was not comprehensive.
Patients will be able to choose which data is encoded and access their own files.
Other persons that are involved in the legal trade of medicinal products, procedures, treatment methods, objects or use such products in the course of their professional activity. The scope and frequency of the monitoring obligations depend on the particular circumstances of the individual case, e.
Back to top of page Overview Population: There are no specific provisions in Germany which prohibit the issuing of information relating to medicinal products to the press.
However, exceptions may apply if the item is i of insignificant value and permanently and clearly visibly labelled with the name of the advertiser or of the advertised product, or ii a trivia of insignificant value, or iii an accessory to the goods which is customary in the trade. However, employed physicians working in medical institutions could be guilty of fraud sectionStGB and breach of trust sectionStGB when receiving kickback payments from pharmaceutical companies.
The reporting period is the calendar year. To what extent may competitors take direct action through the courts in relation to advertising infringements? Advertisements to Healthcare Professionals. With regard to the relationship between the pharmaceutical industry and physicians, the reform of the German Criminal Law to combat corruption in the healthcare sector which entered into force in June can still be considered as the key development.
Heilmittelwerbegesetz by Germany and Ulf Doepner (2000, Book)
However, prohibition of advertisements by competent authorities is very rare in practice. If so, what types of arrangements are permitted? Biosimilars or follow-on biologics are also taking off, with favourable prescription and dispensing requirements after the EU guidelines for biosimilar approval have been issued.